ATNF - 180 Life Sciences Corp. Stock Price, Fair Value and News

1.58USD-0.07 (-4.24%)Market Closed

Market Summary

USD1.58-0.07

Market Closed

-4.24%

ATNF Stock Price

View Fullscreen

ATNF RSI Chart

ATNF Valuation

Market Cap

1.5M

Price/Earnings (Trailing)

-0.09

Price/Sales (Trailing)

70.4

EV/EBITDA

-0.04

Price/Free Cashflow

-0.18

ATNF Price/Sales (Trailing)

ATNF Profitability

EBT Margin

-71657.26%

Return on Equity

1.7K%

Return on Assets

-471.94%

Free Cashflow Yield

-543.5%

ATNF Fundamentals

ATNF Revenue

Revenue (TTM)

25.9K

ATNF Earnings

Earnings (TTM)

-16.2M

Earnings Growth (Yr)

77.54%

Earnings Growth (Qtr)

12.82%

Breaking Down ATNF Revenue

Last 7 days

-18.1%

Last 30 days

-17.3%

Last 90 days

690%

Trailing 12 Months

51.9%

How does ATNF drawdown profile look like?

ATNF Financial Health

Current Ratio

0.45

ATNF Investor Care

Shares Dilution (1Y)

236.43%

Diluted EPS (TTM)

-29.67

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	0	0	0	0
2022	0	0	0	0
2021	0	0	0	0
2020	0	0	0	0
2019	0	0	0	25.9K
2017	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of 180 Life Sciences Corp.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Dec 28, 2023	feldmann marc	acquired	-	-	135,377	-
Dec 15, 2023	woody james n.	bought	4,700	0.188	25,000	chief executive officer
Dec 15, 2023	feldmann marc	sold	-4,700	0.188	-25,000	-
Sep 04, 2023	gold lawrence marshall	acquired	-	-	21,455	-
Sep 04, 2023	marrone pamela g	acquired	-	-	22,388	-
Sep 04, 2023	mcgovern jr. donald a.	acquired	-	-	25,186	-
Sep 04, 2023	ray russell t	acquired	29,178	1.36	21,455	-
Jun 01, 2023	steinman lawrence	bought	22,068	1.226	18,000	-
May 31, 2023	mcgovern jr. donald a.	bought	11,470	1.147	10,000	-
May 19, 2023	mcgovern jr. donald a.	bought	5,800	1.16	5,000	-

Which funds bought or sold ATNF recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	Semmax Financial Advisors Inc.	sold off	-100	-1.00	-	-%
May 16, 2024	Semmax Financial Advisors Inc.	new	-	3.00	3.00	-%
May 15, 2024	AQR Arbitrage LLC	added	1,233	222	1,160	-%
May 15, 2024	CITADEL ADVISORS LLC	added	1,180	16.00	104	-%
May 15, 2024	CITADEL ADVISORS LLC	sold off	-100	-13,871	-	-%
May 15, 2024	Royal Bank of Canada	new	-	-	-	-%
May 15, 2024	Royal Bank of Canada	sold off	-100	-	-	-%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	sold off	-100	-3,723	-	-%
May 15, 2024	TWO SIGMA SECURITIES, LLC	added	1,669	134	299	-%
May 15, 2024	MSD Partners, L.P.	sold off	-100	-378	-	-%

Are Funds Buying or Selling ATNF?

Are funds buying ATNF calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ATNF

No. of Funds

Unveiling 180 Life Sciences Corp.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	armistice capital, llc	9.99%	1,112,480	SC 13G
Apr 14, 2023	feldmann marc	3.4%	141,747	SC 13D/A
Feb 09, 2022	vanguard index funds	2.95%	1,004,406	SC 13G/A
Feb 09, 2022	vanguard group inc	2.95%	1,004,406	SC 13G/A
Feb 07, 2022	nanchahal jagdeep	4.5%	1,520,564	SC 13G/A
Dec 13, 2021	feldmann marc	8.2%	2,834,930	SC 13D/A
Feb 10, 2021	vanguard group inc	6.54%	1,179,639	SC 13G
Feb 08, 2021	vanguard index funds	5.93%	1,069,400	SC 13G
Dec 31, 2020	bauer ronald	9.2%	2,280,171	SC 13G
Dec 30, 2020	kbl iv sponsor llc	9.03%	2,223,365	SC 13D/A

Recent SEC filings of 180 Life Sciences Corp.

View All Filings

Date Filed	Form Type	Document
May 15, 2024	10-Q	Quarterly Report
May 15, 2024	8-K	Current Report
May 09, 2024	8-K	Current Report
Apr 29, 2024	10-K/A	Annual Report
Apr 24, 2024	EFFECT	EFFECT
Apr 24, 2024	EFFECT	EFFECT
Apr 22, 2024	POS AM	POS AM
Apr 22, 2024	POS AM	POS AM
Apr 19, 2024	8-K	Current Report
Apr 18, 2024	S-8	Employee Benefits Plan

Peers (Alternatives to 180 Life Sciences Corp.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

180 Life Sciences Corp. News

Latest updates

180 Life Sciences Corp. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q4	2022Q3	2022Q2	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2017Q2
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	55,729
Operating Expenses	-58.9%	1,452,488	3,538,187	3,682,980	4,803,845	5,639,896	-	-	-	4,462,055	4,217,476	4,013,169	2,948,303	2,415,973	731,078	934,199	1,566,862	-	-
S&GA Expenses	-100.0%	-	2,433,193	2,762,076	4,008,852	5,053,855	-	-	-	2,490,051	3,519,605	2,678,231	2,542,231	-2,751,361	1,786,122	3,513,039	995,328	4,820,828	-
R&D Expenses	-100.0%	-	972,113	789,441	578,309	503,360	-	-	-	324,668	316,473	246,613	99,899	-	-	351,005	472,862	-	-
EBITDA Margin	49.1%	-857	-1,684	-2,026	-1,771	-1,527	-612	920	-96.51	-777	-1,102	-1,836	-915	-381	-	-	-	-	-
Interest Expenses	4.7%	12,178	11,634	11,606	7,265	8,339	-	-	-	55,574	5,455	12,246	112,933	594,020	82,990	172,498	152,916	-	-
Income Taxes	99.8%	-4,389	-2,345,025	-	-	-	-	-	-	-6,617	-5,612	-5,571	-5,404	-5,253	-5,135	-4,936	-5,102	-227,079	-
Earnings Before Taxes	90.2%	-1,231,494	-12,610,785	-3,680,169	-4,762,078	-22,685,027	-	-	-	1,029,600	18,291,244	-23,464,707	-16,203,989	-7,946,016	-834,553	262,446	-2,386,362	-25,820,100	-
EBT Margin	49.1%	-858	-1,685	-2,027	-1,772	-1,528	-614	918	-99.44	-784	-1,130	-1,867	-952	-420	-	-	-	-	-
Net Income	88.0%	-1,227,105	-10,265,760	-3,680,169	-4,762,078	-21,742,278	-	-	-	1,036,217	18,296,856	-23,459,136	-16,198,585	-7,940,763	-829,418	267,383	-2,381,260	-25,593,021	-
Net Income Margin	50.7%	-768	-1,559	-1,991	-1,736	-1,492	-614	918	-98.76	-783	-1,129	-1,866	-952	-419	-	-	-	-	-
Free Cashflow	-21.7%	-2,160,014	-1,775,475	-3,116,843	-3,869,891	-2,926,755	-3,596,366	-3,531,533	-2,072,931	-5,027,530	-4,002,668	-4,011,185	-6,330,045	-3,216,392	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-34.6%	3,442	5,259	4,958	13,667	14,922	19,650	34,336	53,358	59,677	62,714	65,070	56,265	60,112	55,533	11,024	12,626	12,368	51,884	51,573	50,237	66,471
Current Assets	-49.0%	1,855	3,640	3,371	2,934	4,196	8,928	6,515	4,647	8,957	11,201	13,634	4,046	8,298	4,015	721	1,186	388	748	901	209	145
Cash Equivalents	-65.8%	676	1,976	2,663	2,009	2,646	6,970	3,589	1,625	5,669	8,225	11,688	1,836	6,053	2,109	33.00	70.00	98.00	83.00	836	110	135
Goodwill	-	-	-	-	-	-	9,063	13,966	12,411	36,324	36,988	36,896	37,561	37,183	36,901	-	-	-	36,423	-	-	-
Liabilities	-18.4%	4,396	5,387	5,107	6,951	7,783	8,306	8,261	10,566	18,773	23,391	27,929	53,549	37,403	25,247	6,277	4,142	7,238	13,314	6,813	5,456	5,203
Current Liabilities	-19.4%	4,080	5,063	4,807	4,273	5,122	5,658	4,725	6,966	15,077	19,699	24,225	49,799	33,622	21,421	6,277	4,142	3,213	9,641	2,788	1,431	1,178
Shareholder's Equity	-647.2%	-954	-127	-	6,716	7,140	11,344	26,075	42,791	40,905	39,323	37,141	2,716	22,709	30,287	35,467	35,882	34,747	38,571	5,000	5,000	5,000
Retained Earnings	-0.8%	-128,413	-127,343	-126,116	-115,850	-112,170	-107,408	-85,666	-64,179	-67,118	-68,682	-69,718	-88,015	-64,556	-48,357	-7,933	-4,583	852	-37,473	1,360	1,382	1,393
Additional Paid-In Capital	0.2%	130,354	130,117	128,815	125,466	122,195	121,638	115,427	108,786	107,930	107,187	106,154	89,496	86,436	78,005	12,680	9,583	4,147	75,890	3,639	3,618	3,607
Shares Outstanding	59.5%	853	535	355	197	197	197	103	90.00	90.00	90.00	80.00	83.00	74.00	69.00	-	-	-	-	-	-	-
Float	-	-	-	-	5,851	-	25,377	-	25,377	-	271,883	-	20,792	-	-	-	-	-	-	-	50,159	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	52.2%	-1,033	-2,160	-1,775	-3,116	-3,869	-2,926	-3,596	-3,531	-2,072	-5,027	-4,002	-4,011	-6,330	-3,216	-53.97	-192	-409	-2,158	-216	-636	-307
Share Based Compensation	-	236	-	-	-	557	-	-	-	-	-	-	-	-	-1,506	-	-	-	-	-	-	-
Cashflow From Investing	-	-	-	-	-	-	-	-	-	-	-	-	-	-	12,878	973	707	-66.86	-69,979	-388	16,654	53,005
Cashflow From Financing	-118.0%	-264	1,468	2,447	2,462	-469	6,396	5,488	-494	-515	1,549	13,729	-228	10,363	-9,225	147	12.00	333	-38,962	1,330	-16,041	-52,834

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

ATNF Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating Expenses:
Research and development	$ 365,186	$ 578,309
Research and development - related parties	170,542	216,684
General and administrative	1,556,740	4,008,852
Total Operating Expenses	2,092,468	4,803,845
Loss From Operations	(2,092,468)	(4,803,845)
Other (Expense) Income:
Other income	1,039,364
Interest expense	(16,449)	(11,556)
Change in fair value of derivative liabilities	(191)	53,323
Total Other (Expense) Income, Net	1,022,724	41,767
Loss Before Income Taxes	(1,069,744)	(4,762,078)
Income tax benefit
Net Loss	(1,069,744)	(4,762,078)
Other Comprehensive Income (Loss):
Foreign currency translation adjustments	6,460	663
Total Comprehensive Loss	$ (1,063,284)	$ (4,761,415)
Basic and Diluted Net Loss per Common Share
Basic (in Dollars per share)	$ (1.68)	$ (24.15)
Diluted (in Dollars per share)	$ (1.68)	$ (24.15)
Weighted Average Number of Common Shares Outstanding:
Basic (in Shares)	638,339	197,219
Diluted (in Shares)	638,339	197,219

ATNF Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Assets
Cash	$ 675,977	$ 1,975,799
Prepaid expenses and other current assets	1,178,971	1,664,107
Total Current Assets	1,854,948	3,639,906
Intangible assets, net	1,586,792	1,619,570
Total Assets	3,441,740	5,259,476
Liabilities and Stockholders’ Deficit
Accounts payable	1,784,150	1,892,611
Accrued expenses	1,416,790	1,869,814
Loans payable - current portion	772,334	1,034,124
Derivative liabilities	249	58
Total Current Liabilities	4,080,307	5,062,616
Loans payable - noncurrent portion	16,544	19,936
Deferred tax liability	299,355	304,657
Total Liabilities	4,396,206	5,387,209
Commitments and contingencies (Note 8)
Stockholders’ Deficit:
Preferred stock value
Common stock, $0.0001 par value; 100,000,000 shares authorized; 852,772 and 534,719 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	86	54
Additional paid-in capital	130,353,728	130,117,209
Accumulated other comprehensive income	(2,894,879)	(2,901,339)
Accumulated deficit	(128,413,401)	(127,343,657)
Total Stockholders’ Deficit	(954,466)	(127,733)
Total Liabilities and Stockholders’ Deficit	3,441,740	5,259,476
Related Party
Liabilities and Stockholders’ Deficit
Accounts payable – related parties	53,076	266,009
Accrued expenses - related parties	53,708
Class C Preferred Stock
Stockholders’ Deficit:
Preferred stock value
Class K Preferred Stock
Stockholders’ Deficit:
Preferred stock value

About 180 Life Sciences Corp.

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. 180 Life Sciences Corp. is headquartered in Palo Alto, California.

CEO	Dr. James N. Woody M.D., Ph.D.
WEBSITE	https://180lifesciences.com
INDUSTRY	Biotechnology
EMPLOYEES	5

180 Life Sciences Corp. Frequently Asked Questions

What is the ticker symbol for 180 Life Sciences Corp.? What does ATNF stand for in stocks?

ATNF is the stock ticker symbol of 180 Life Sciences Corp.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of 180 Life Sciences Corp. (ATNF)?

As of Fri May 17 2024, market cap of 180 Life Sciences Corp. is 1.49 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ATNF stock?

You can check ATNF's fair value in chart for subscribers.

What is the fair value of ATNF stock?

You can check ATNF's fair value in chart for subscribers. The fair value of 180 Life Sciences Corp. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of 180 Life Sciences Corp. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ATNF so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is 180 Life Sciences Corp. a good stock to buy?

The fair value guage provides a quick view whether ATNF is over valued or under valued. Whether 180 Life Sciences Corp. is cheap or expensive depends on the assumptions which impact 180 Life Sciences Corp.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ATNF.

What is 180 Life Sciences Corp.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, ATNF's PE ratio (Price to Earnings) is -0.09 and Price to Sales (PS) ratio is 70.4. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ATNF PE ratio will change depending on the future growth rate expectations of investors.